Idiopathic Clinical Trials

376 recruitingLast updated: May 11, 2026

There are 376 actively recruiting idiopathic clinical trials across 58 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Paris, France, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Idiopathic Trials at a Glance

376 actively recruiting trials for idiopathic are listed on ClinicalTrialsFinder across 6 cities in 58 countries. The largest study group is Not Applicable with 118 trials, with the heaviest enrollment activity in New York, Paris, and Los Angeles. Lead sponsors running idiopathic studies include Assistance Publique - Hôpitaux de Paris, Second Affiliated Hospital of Wenzhou Medical University, and Tongji Hospital.

Treatments under study

About Idiopathic Clinical Trials

Looking for clinical trials for Idiopathic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Idiopathic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Idiopathic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 376 trials

Recruiting
Phase 2

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Idiopathic CD4-PositiveT-Lymphocytopenia
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT02015013
Recruiting
Phase 2

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Idiopathic Short Stature
BioMarin Pharmaceutical100 enrolled47 locationsNCT06382155
Recruiting

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Cryptococcal MeningitisWartsIdiopathic CD4+ Lymphocytopenia
National Institute of Allergy and Infectious Diseases (NIAID)950 enrolled1 locationNCT00867269
Recruiting
Phase 2

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

Idiopathic Pulmonary FibrosisPulmonary Fibrosis, Interstitial Lung Disease
Vejle Hospital140 enrolled5 locationsNCT06714123
Recruiting

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Duke University3,000 enrolled44 locationsNCT01915511
Recruiting
Phase 2

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics120 enrolled11 locationsNCT06968845
Recruiting
Phase 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Mediar Therapeutics164 enrolled69 locationsNCT06967805
Recruiting
Not Applicable

Support System Design for Adolescent Scoliosis Orthosis Wear

Adolescent Idiopathic Scoliosis (AIS)Adherence
Shanghai Jiao Tong University School of Medicine18 enrolled1 locationNCT07574229
Recruiting

Cyberchondria in Adolescents With Idiopathic Scoliosis

Scoliosis Idiopathic AdolescentCyberchondria
Izmir Democracy University100 enrolled1 locationNCT07481071
Recruiting
Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Mannkind Corporation24 enrolled9 locationsNCT07344558
Recruiting
Phase 1

A Study of AZD0120 in Autoimmune Diseases

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting
Not Applicable

Feasibility of a Diet Intervention for Juvenile Arthritis

Juvenile Idiopathic ArthritisArthritis, JuvenileArthritis, Childhood
The Hospital for Sick Children54 enrolled7 locationsNCT06474546
Recruiting
Phase 3

Evaluation of Analgesia for Spine Fusion Elective Surgery in Children

Idiopathic Scoliosis
Senthil Sadhasivam500 enrolled2 locationsNCT06626503
Recruiting

Natural History of Noncirrhotic Portal Hypertension

Cystic FibrosisTurner SyndromeImmunologic Deficiency Syndrome+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)400 enrolled1 locationNCT02417740
Recruiting
Phase 1

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Neuromyelitis Optica Spectrum Disorder (NMOSD)+6 more
Polina Stepensky120 enrolled1 locationNCT07085676
Recruiting
Phase 2

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Juvenile Idiopathic Arthritis
Sanofi51 enrolled31 locationsNCT02991469
Recruiting
Not Applicable

Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients

Idiopathic Short Stature
University Hospital, Montpellier200 enrolled1 locationNCT05858606
Recruiting
Phase 2

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim20 enrolled3 locationsNCT06241560
Recruiting
Phase 1

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955